The Novel Angiotensin-(1–7) Analog, A-1317, Improves Insulin Resistance by Restoring Pancreatic β-Cell Functionality in Rats With Metabolic Syndrome

Maria Andréa Barbosa¹, Claudiane Maria Barbosa¹, Taynara Carolina Lima¹, Robson Augusto Souza dos Santos²* and Andréia Carvalho Alzamora¹,3*

¹ Núcleo de Pesquisa em Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, Brazil, ² Departamento de Fisiologia e Biofísica, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ³ Departamento de Ciências Biológicas, Instituto de Ciências Exatas e Biológicas, Ouro Preto, Brazil

In previous studies we have shown that oral Ang-(1–7) has a beneficial therapeutic effect on cardiometabolic disturbances present in metabolic syndrome (MetS). Based on the fact that Ang-(1–7) acts through release of nitric oxide (NO), a new peptide, A-1317 was engineered adding the amino acid L-Arginine, the NO precursor, to the N-terminal portion of the Ang-(1–7). Therefore, in a single molecule the substrate and the activator of NO are combined. In the present study, we evaluated the effect of A-1317 oral treatment on liver-glucose metabolism in MetS induced by high fat (HF) diet in rats. Rats were subjected to control (AIN-93M, CT) or HF diets for 15 weeks to induce MetS and treated with A-1317, Ang-(1–7) included into hydroxypropyl-β-cyclodextrin (HPβCD) or empty HPβCD (E), in the last 7 weeks. At the end of 15 weeks, hemodynamic, biometric, and biochemical parameters, redox process, and qRT-PCR gene expression of NO synthase and RAS components were evaluated in the liver. HF/E rats increased body mass gain, adiposity index, despite the reduction in food intake, increased plasma leptin, total cholesterol, triglycerides, ALT, fasting blood glucose, OGTT and insulin, HOMA-IR and MAP and HR. Furthermore, the MetS rats presented increased in liver angiotensinogen, AT1R, ACE mRNA gene expression and concentration of MDA and carbonylated protein. Both Ang-(1–7) and A-1317 oral treatment in MetS rats reverted most of these alterations. However, A-1317 was more efficient in reducing body mass gain, adiposity index, despite the reduction in food intake, increased plasma leptin, total cholesterol, triglycerides, ALT, fasting blood glucose, OGTT and insulin, HOMA-IR and MAP and HR. Furthermore, the MetS rats presented increased in liver angiotensinogen, AT1R, ACE mRNA gene expression and concentration of MDA and carbonylated protein. Both Ang-(1–7) and A-1317 oral treatment in MetS rats reverted most of these alterations. However, A-1317 was more efficient in reducing body mass gain, ALT, AST, total cholesterol, insulin, fasting blood glucose, ameliorating β cell capacity by increasing HOMA-β and QUICKI, whereas Ang-(1–7) reduced HOMA-β and QUICKI. In addition, Ang-(1–7) increased Mas and AKT liver mRNA gene expression, while A-1317 increased both Mas and MRGD and AMPK liver mRNA gene expression, suggesting a distinct pathway of action of Ang-(1–7) and A-1317 in MetS rats. Taken together, our data showed that treatment with A-1317 was able to ameliorate MetS disorders and suggested that this effect was mainly via MRGD via activation of AMPK and increasing β cell function.

Keywords: metabolic syndrome, angiotensin-(1–7), A-1317, liver metabolism, Mas, Mas-related G protein-coupled receptor member D, adenosine monophosphate activated protein kinase, pancreatic β-cell
INTRODUCTION

High fat diet (HF) and/or physical inactivity can induce metabolic syndrome (MetS) which is characterized by cardiometabolic disorders such as insulin resistance (IR), high blood pressure and central obesity (Alberti et al., 2009; Zacarias et al., 2017; Barbosa et al., 2019). These disorders are related to redox imbalance resulting in higher formation of reactive oxygen species such as superoxide and hydroxyl radicals, which can lead to mitochondrial dysfunction and accumulation of oxidized proteins and lipids (Estadella et al., 2013; Peluso et al., 2017; Zacarias et al., 2017; Vona et al., 2019). In addition, HF diet induces liver damage related to various disorders occurring in the MetS such as IR, dyslipidemia, and increased adiposity (Rosselli et al., 2014; Zacarias et al., 2017; Barbosa et al., 2019; Figueiredo et al., 2019). Additionally, in pancreatic β-cells, different concentrations of nitric oxide (NO) exerts positive or negative regulation of insulin secretion (Meares et al., 2011) and thus improving or worsening the state of IR (Kaneko and Ishikawa, 2013). Furthermore, some studies have suggested that adenosine monophosphate activated protein kinase (AMPK), an enzyme that plays a role in cellular energy homeostasis, acts as a negative regulator of insulin secretion in pancreatic β-cells (Fu et al., 2013), regulating NO bioavailability by phosphorylating eNOS (Meares et al., 2011; Patel et al., 2016).

In the renin angiotensin system (RAS), the angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1–7) [Ang-(1–7)]/Mas-related G protein-coupled receptor (Mas) axis is a counter-regulator of the actions of the angiotensin-converting enzyme (ACE)/angiotensin II (Ang II)/angiotensin II type 1 receptor (AT1R) axis in different disease states (Dominici et al., 2014; Santos et al., 2018). Ang-(1–7) through activation of Mas (Santos et al., 2003) acts mainly through NO and protein kinase B (AKT), a serine/threonine specific protein kinase, that plays a key role in glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration being proposed as a therapeutic strategy for cardiometabolic diseases (Sampaio et al., 2007; Dias-Peixoto et al., 2008; Whitaker and Molina, 2014; Santos et al., 2018). On the other hand, studies show that in addition to Mas, some effects of Ang-(1–7) can also be mediated through Mas-related G protein-coupled receptor member D (MRGD) (Tetzner et al., 2016; Gunarathne et al., 2019) via AMPK (Liu et al., 2019).

In prevention studies, oral administration of Ang-(1–7) improved body mass, adiposity index, plasma triglycerides levels, glucose tolerance, insulin sensitivity in rats and mice fed with HF (Oliveira Andrade et al., 2014; Williams et al., 2016) and fructose (Giani et al., 2009; Muñoz et al., 2012) diets. Additionally, in recent studies (Barbosa et al., 2019; Figueiredo et al., 2019) we have shown that oral treatment with Ang-(1–7) in rats, with established MetS induced by HF diet, was effective in restoring biometric, biochemical parameters, redox process, and RAS components in the liver and gastrocnemic muscle (Figueiredo et al., 2019). Also, oral treatment with Ang-(1–7) was able to remodel the white and brown adipose tissue (Barbosa et al., 2019). This data set shows the effectiveness of oral Ang-(1–7) treatment in restoring different MetS disorders already established in rats.

Given the evidence that Ang-(1–7) treatment is efficient in the treatment of MetS and that these benefits may occur through NO, here we studied whether the addition of L-Arginine in the N-terminal portion of Ang-(1–7), A-1317 compound, could enhance the beneficial effect observed by Ang-(1–7) in the already established MetS. This compound was previously used in our laboratory for treatment of muscular dystrophy (Oliveira, 2019).

METHODS

Animals

The study used male Fischer rats, aged 4 weeks (71.7 ± 1.04 g, n = 60), from the Animal Science Center (CCA/UFOP) of the Federal University of Ouro Preto (UFOP, Brazil). The animals were kept in individual cages under controlled temperature (25 ± 1°C) and a light–dark cycle of 12 h–12 h. Throughout the experiment, the animals had free access to water and diet. All procedures were performed in accordance with the Guidelines for Ethics in Care of Experimental Animals. The project was approved by the animal ethics committee of the Federal University of Ouro Preto protocol 2016/51.

Study Design

After weaning, the animals were fed with control diet (AIN-93 M) or high fat diet (HF, 37% lard, Table 1) for 15 weeks and food intake was evaluated weekly. In the eight week of diets, MetS effects were analyzed on body mass, fasting glucose, plasma levels of total cholesterol, high density lipoprotein (HDL), and triacylglycerol using commercial kits (Labtest, Lagoa Santa, MG, Brazil). The mean arterial pressure (MAP) and heart rate (HR) were evaluated by digital tail plethysmography (Panlab, LES001). Additionally, oral glucose tolerance test (OGTT) was performed by assessing glycemia by gavage administration of 40% glucose solution (1 g/kg) to the animals after 10, 20, 30, 60, 90, and 120 min by glucose analysis (glycosimeter, Accu-chek®, and the area under the curve (AUC) was calculated using trapezoidal analysis (Song et al., 2004). After eight weeks of the diets, orally by gavage, the treatment with HP/CD/A-1317 (42 µg/kg/day), HP/CD/Ang-(1–7) (40 µg/kg/day) or HP/CD/A-1317 (42
The experimental groups were: 1) HF/CD/A-1317 (n = 10): rats fed with HF diet and treated with HP 1317 during the last seven weeks of diet; 2) CT/CD (n = 10): rats fed with CT diet and treated with HP 1317 during the last seven weeks of diet; 3) CT/A-1317 (n = 10): rats fed with CT diet and treated with HP/A-1317 during the last seven weeks of diet; 4) HF/CD (n = 10): rats fed with HF diet and treated with empty HP/A-1317 during the last seven weeks of diet; 5) HF/CD/A-1317 (n = 10): rats fed with HF diet and treated with HP/A-1317 during the last seven weeks of diet; 6) HF/CD/A-1317 (n = 10): rats fed with HF diet and treated with HP/A-1317 during the last seven weeks of diet.

Superoxide Dismutase Activity
Frozen liver samples (100 mg) were homogenized in phosphate buffer (pH 7.4) and centrifuged at 12,000g for 10 min at 4°C. The activity of the enzyme superoxide dismutase (SOD) was evaluated indirectly with an ELISA reader at 570 nm, based on the ability of this enzyme to eliminate the superoxide anion, decreasing the reduction of thiazylol blue tetrazolium bromide and converting superoxide anion to hydrogen peroxide and thereby reducing the auto oxidation rate of pyrogallol (Dietrich et al., 2000). The results were expressed as U/mg protein, in which a unit of SOD is defined as the amount of enzyme required for 50% inhibition of thiazoyl blue tetrazolium bromide reduction.

Thiobarbituric Acid-Reactive Substances and Carbonyl Protein
Malondialdehyde (MDA) concentrations were determined using thiobarbituric acid reactive substance (TBARS) concentrations. Liver samples (100 mg) were homogenized in KPE (potassium phosphate–EDTA) buffer (pH 7.4) and centrifuged (10,000g, 10 min, at 4°C). The supernatant was collected and used as the biological sample. Briefly, the samples from the homogenates were mixed with 1 ml of 10% trichloroacetic acid and 1 ml of 0.67% thiobarbituric acid and then heated in a boiling water bath for 30 min. TBARS was determined from the absorbance at 532 nm. The absorbance of the supernatant was determined at 370 nm. Both series of data are expressed in nmol/mg of protein. The contents of carbonylated protein were determined according to the method of Levine et al. (1990). Data were expressed as nmol/mg protein.

Gene Expression Analysis
In separated groups of rats, qRT-PCR was performed in the liver. The total RNA from the liver was isolated with TRI reagent® (Sigma-Aldrich) according to the manufacturer’s protocol. All isolated RNA was quantified by spectrophotometry, and the optical density was estimated from the 260/280 nm absorbance
A reverse transcriptase reaction was performed using SuperScript™ III (Invitrogen Life Technologies) for first-strand cDNA synthesis. Real-time PCR was carried out following the generation of first-strand CDNA. A PCR for each sample was carried out in triplicate for all cDNAs and for the 18s ribosomal control and were used SYBR® Green PCR Master Mix (Applied Biosystems, Rockford, USA). The analyzed genes are described in Table 2. The analyses were performed by a relative method for quantifying gene expression (comparative Cq, ΔCq), which allows one to quantify differences among samples in the level of expression of a specific target. The expression levels were normalized for the amount of the reference gene (Rplp2) on each plate. The results were obtained with a formula that considers the amount of the target gene normalized to the calibrator gene, given by (2^−ΔCq).

**Statistical Analysis**

Results are expressed as means ± SEM. Data were analyzed for Kolmogorov–Smirnov normality and followed the standard normal distribution. After, they were evaluated by two-way ANOVA, followed by Tukey’s post-test. Statistical analyses were performed with GraphPad Prism software (version 6.0, San Diego, USA). Statistical significance was set at p < 0.05.

**RESULTS**

**Evaluation of MetS Establishment**

After eight weeks of diets, HF rats showed characteristic disorders of the MetS such as increased body mass, fasting blood glucose levels, glucose area under the curve (AUC), serum triacylglycerol, MAP, HR, and reduction in HDL cholesterol levels compared to CT rats. There was no significant difference in total cholesterol levels in all the evaluated groups (Table 3).

**Oral A-1317 Treatment Decreases Body Mass Gain**

HF/E, HF/Ang-(1–7) and HF/A-1317 rats showed decreased in food intake and no difference in caloric intake compared to rats CT/E. However, oral treatments with Ang-(1–7) or A-1317 decreased the adiposity index compared to HF/E rats. In addition, only treatment with A-1317 decreased body mass gain compared to HF/E rats. There was no difference in liver mass in all groups (Table 4).

**Oral A-1317 Treatment Improves Total Cholesterol Plasma Levels and Liver Damage**

HF/E rats showed increased plasma levels of leptin, total cholesterol, triglycerides and ALT compared to CT/E rats. Treatment with Ang-(1–7) or A-1317 decreased leptin and triglyceride levels compared to HF/E rats. In addition, only treatment with A-1317 decreased total cholesterol, ALT, and AST levels compared to HF/E rats (Table 5).

**Oral A-1317 Treatment Improves Insulin Resistance by Increasing β-Cells’ Functional Capacity**

HF/E rats presented increased MAP and HR, fasting blood glucose, plasma insulin levels, OGTT, HOMA-IR and decreased QUICKI compared to CT/E rats (Figures 1A–H). Treatment with Ang-(1–7) and A-1317 decreased MAP, HOMA-IR compared to CT/E rats and OGTT compared to CT/E and HF/E rats (Figures 1A, D, F). In addition, HF/Ang-(1–7) rats showed decreased fasting blood glucose and HOMA-β compared to HF/E rats and QUICKI compared to CT/E rats (Figures 1C, G, H). Only, treatment with A-1317 decreased insulin levels compared to HF/E rats and fasting blood glucose compared to CT/E, HF/E, HF/Ang-(1–7) and increased HOMA-β compared to CT/E and HF/Ang-(1–7) rats and QUICKI

| Gene          | Accession number (RGID) | Primer sequences (5'–3') |
|---------------|-------------------------|-------------------------|
| Angiotensinogen | 13432.2                | F 5’-CTGTGAAAGGAGGGAGCTGC-3' |
| ACE           | 012544.1                | R 5’-CAAGAAAGGCCTCTGACGACG-3' |
| Agtr1a/b (AT1R) | 030985.4                | F 5’-TCATCTCTCGGATATGCTGCTG-3' |
| ACE2          | 001012006.1             | F 5’-TGAGATGGAGGGAGGGATCG-3' |
| Mas           | 012757.2                | R 5’-GCTCTCTCAACTGATGCTGCTG-3' |
| AKT           | 016988.2                | R 5’-GAGGAGCTCTAGGGAGGATGCT-3' |
| AMPK          | 023991.1                | R 5’-GGGCAACGGTTGCCCTGCTG-3' |
| MRGD          | 001001506.1             | F 5’-TGACCGAGCTGTGACAGAG-3' |
| eNOS          | 021838.2                | R 5’-GTCAGACGTGATCTCTCCCTG-3' |
| bNOS          | 012611.3                | R 5’-ACCTGCTGCTCTCCCTTCCCT-3' |
| Rplp2         | 001108150               | F 5’-CTGTGAAAGGAGGGAGCTGC-3' |

Primers used (Forward and Reverse).

| TABLE 3 | Evaluation of MetS establishment in rats after 8 weeks of HF diet. |
|----------|------------------------------------------------------------------|
| Parameters | CT/E   | HF/E   |
| Body mass (g)   | 264 ± 3.1 | 307 ± 6.8* |
| Blood glucose level (mg/dl) | 124.9 ± 5.34 | 172.7 ± 9.242* |
| OGTT (AUC)   | 14460 ± 415.6 | 16594 ± 441.2* |
| Total cholesterol (mg/dl) | 57.8 ± 3.4 | 64.0 ± 4.6 |
| HDL cholesterol (mg/dl) | 37.6 ± 1.7 | 31.27 ± 0.9* |
| Triacylglycerol (mg/dl) | 41.4 ± 3.7 | 59.2 ± 3.9* |
| MAP (mmHg)   | 108.4 ± 2.1 | 121.4 ± 5.1* |
| HR (beats/min) | 384 ± 11.3 | 418 ± 3.9* |
| n            | 9-20 | 9-20 |

*p < 0.05 compared to CT/E group. Values are expressed as mean values ± standard error of the mean and analyzed using unpaired student t-test. OGTT, oral glucose tolerance test; AUC, area under the curve; MAP, mean arterial pressure; HR, heart rate; n = number of animals.
compared to HF/E and HF/Ang-(1–7) rats (Figures 1C, E, G, H).

**Oral A-1317 Treatment Increases Mas and MRGD mRNA Gene Expression in the Liver**

HF/E rats increased angiotensinogen, ACE, AT1R mRNA gene expression compared to CT/E rats (Figures 2A–C). However, treatment with Ang-(1–7) or A-1317 decreased AT1R mRNA gene expression compared to CT/E rats. In addition, treatment with Ang-(1–7) decreased ACE mRNA gene expression and increased ACE2 mRNA gene expression compared to HF/E and Mas mRNA gene expression compared to CT/E and HF/E (Figures 2B–E). Furthermore, the treatment with A-1317 increased angiotensinogen mRNA gene expression compared to CT/E and HF/Ang-(1–7) and ACE2 mRNA gene expression compared to CT/E and HF/E. Finally, treatment with A-1317 increased Mas and MRGD mRNA gene expression compared to CT/E, HF/E, and HF/Ang-(1–7) (Figures 2A, D–F).

**Oral A-1317 Treatment Decreases Redox Process in the Liver**

HF/E rats showed increased concentrations of MDA and carbonyl protein compared to CT/E rats (Figures 3A, B). Treatment with Ang-(1–7) or A-1317 decreased concentrations of MDA, carbonyl protein, and iNOS mRNA gene expression compared to HF/E rats and increased eNOS mRNA gene expression and SOD activity compared to HF/E. However, treatment with A-1317 increased eNOS mRNA gene expression and SOD activity compared to CT/E rats, too (Figures 3C–E).

**Oral A-1317 Treatment Increases AMPK mRNA Gene Expression in the Liver**

Treatment with Ang-(1–7) increased AKT mRNA gene expression compared to HF/E rats (Figure 4A). On the other hand, treatment with A-1317 did not change AKT mRNA gene expression but increased AMPK mRNA gene expression compared to CT/E and HF/Ang-(1–7) rats (Figure 4B).

---

**TABLE 4 |** Feed intake and biometric parameters of rats fed with CT or HF for 15 weeks and treated with HP/CD/A-1317 or HP/CD/Ang-(1–7) during the last 7 weeks of the diet.

| Parameters                      | Experimental Groups |
|---------------------------------|---------------------|
|                                 | CT/E               | CT/Ang-(1–7) | CT/A-1317 | HF/E   | HF/Ang-(1–7) | HF/A-1317 |
| Food intake (g)                 | 92.0 ± 4.3         | 82.4 ± 1.4 | 90.0 ± 2.8 | 72.3 ± 3.0* | 73.4 ± 1.0* | 66.1 ± 3.2* |
| Caloric intake (kcal)           | 349.5 ± 16.4       | 313.1 ± 5.5 | 342.2 ± 10.7 | 391.4 ± 15.8 | 381.9 ± 5.4 | 343.5 ± 5.3 |
| Body mass gain (g)              | 230.3 ± 10.1       | 225.6 ± 6.2 | 239.3 ± 10.1 | 317.1 ± 8.8* | 282.7 ± 11.8* | 268.4 ± 9.9* |
| Liver (g/100 rat mass)          | 2.55 ± 0.09        | 2.31 ± 0.10 | 2.66 ± 0.07 | 2.47 ± 0.07 | 2.34 ± 0.04 | 2.45 ± 0.06 |
| Adiposity index                 | 7.05 ± 0.3         | 4.98 ± 0.4 | 6.54 ± 0.5 | 10.96 ± 0.1* | 7.89 ± 0.57* | 8.75 ± 0.35* |
| n                               | 6–10               | 6–10      | 6–10      | 6–10    | 6–10     | 6–10     |

*p < 0.05 compared to CT/E group. *p < 0.05 compared to HF/E group. (ANOVA two way followed by Tukey's test), expressed as mean values ± standard error of the mean. n = number of animals.

**TABLE 5 |** Biochemical parameters of rats fed with CT or HF for 15 weeks and treated with HP/CD/A-1317 or HP/CD/Ang-(1–7) during the last 7 weeks of the diet.

| Parameters                      | Experimental Groups |
|---------------------------------|---------------------|
|                                 | CT/E               | CT/Ang-(1–7) | CT/A-1317 | HF/E   | HF/Ang-(1–7) | HF/A-1317 |
| Leptin (ng/dl)                  | 5.25 ± 1.35        | 5.55 ± 1.14 | 7.65 ± 1.42 | 19.40 ± 1.40* | 6.66 ± 0.63* | 4.92 ± 0.27* |
| Total cholesterol (mg/dl)       | 40.2 ± 3.2         | 51.8 ± 3.5 | 47.2 ± 1.9 | 74.5 ± 7.2* | 55.9 ± 5.2 | 50.5 ± 5.6* |
| Triacylglycerol (mg/dl)         | 37.2 ± 4.9         | 48.1 ± 4.9 | 49.1 ± 5.0 | 68.2 ± 5.9* | 40.7 ± 4.5* | 43.4 ± 7.9* |
| ALT (U/L)                       | 66.6 ± 2.0         | 75.6 ± 15.0 | 64.1 ± 4.5 | 126.3 ± 28.1* | 72.6 ± 3.6 | 62.7 ± 1.6* |
| AST (U/L)                       | 174.9 ± 13.5       | 133.4 ± 19.8 | 140.2 ± 12.6 | 219.4 ± 17.6 | 171.3 ± 17.6 | 151.8 ± 6.4* |
| Creatinine (mg/dl)              | 0.575 ± 0.04       | 0.637 ± 0.03 | 0.600 ± 0.02 | 0.675 ± 0.02 | 0.575 ± 0.02 | 0.588 ± 0.01 |
| Albumin (g/dl)                  | 3.34 ± 0.08        | 3.47 ± 0.06 | 3.30 ± 0.10 | 3.46 ± 0.06 | 3.47 ± 0.08 | 3.32 ± 0.10 |
| Total proteins (g/dl)           | 8.06 ± 0.12        | 7.71 ± 0.49 | 6.65 ± 0.90 | 7.32 ± 0.10 | 7.21 ± 0.13 | 7.49 ± 0.18 |
| n                               | 8                   | 8           | 8           | 8        | 8         | 8         |

*p < 0.05 compared to CT/E group. *p < 0.05 compared to HF/E group. (ANOVA two way followed by Tukey's test), expressed as mean values ± standard error of the mean. n = number of animals.
FIGURE 1 | Evaluation of hemodynamic parameters and insulin resistance. Evaluation of mean blood pressure (MAP, mmHg, A), heart rate (HR, beats/min, B), Fasting blood glucose (mg/dL, C), area under the curve (AUC) of blood glucose during oral glucose tolerance test (OGTT, D), Insulin levels (pmol/L, E), model assessment of IR homeostasis (HOMA-IR, F) = [fasting insulin (FI) x fasting glucose (FG) / 22.5], homeostasis evaluation model of the functional capacity of β-cells (HOMA-β, G) = (20 x FI) / (FG 3.5), quantitative insulin sensitivity check index (QUICKI, H) = 1/[LOG(FI)/LOG(FG)] in rats fed with high-fat (HF) or control (CT, n=6-8) diet for 15 weeks and treated with empty (HPbCD), Ang-(1-7) or A-1317 during the last 7 weeks of diets. Values are expressed as mean ± SEM and analyzed using two-way analysis of variance (ANOVA) followed by Tukey’s post-test.*p<0.05 compared to CT/E group, #p<0.05 compared to HF/E group, &p<0.05 compared to HF/Ang-(1-7) group.
DISCUSSION

In the present study, Ang-(1–7) and A-1317 oral treatments in MetS rats have similar beneficial effects on glucose metabolism and blood pressure. However, oral treatment with the A-1317 compound was more efficient in restoring IR by ameliorating pancreatic β cell functionality. In addition, Ang-(1–7) increased Mas and AKT liver mRNA gene expression while A-1317 increased both, Mas and MRGD, and AMPK. Taken together, our data showed that treatment with A-1317 was able to ameliorate MetS disorder probably by Mas and MRGD via activation of AMPK and increasing pancreatic β cell function.

Both Ang-(1–7) and A-1317 oral treatment in MetS rats, besides maintaining similar caloric intake, improved metabolism by reducing adiposity index, fasting blood glucose, OGTT, HOMA-IR, triglycerides, lipid peroxidation, AT1R, iNOS liver mRNA gene expression and carbonylated protein and MAP and increased eNOS and ECA2 liver mRNA gene expression and SOD activity. These beneficial effects induced by oral treatment with Ang-(1–7) in MetS rats are in agreement with previous studies from our laboratory using the same experimental protocol (Barbosa et al., 2019; Figueiredo et al., 2019) and in the literature studies in prevention of MetS (Giani et al., 2009; Oliveira Andrade et al., 2014; Santos et al., 2014; Liu et al., 2019). However, A-1317 peptide was more effective than Ang-(1–7) in reducing body mass gain, ALT, AST, total cholesterol, insulin, fasting blood glucose and in increasing AMPK mRNA gene expression, and β cell capacity showed by enhancing HOMA-β and QUICKI (Sarafidis et al., 2007), whereas

![FIGURE 2 | Evaluation of the mRNA components expressions of the renin angiotensin system in the live. Angiotensinogen (A), angiotensin-converting enzyme (ACE, B), angiotensin II receptor type 1 (AT1R, C), angiotensin-converting enzyme 2 (ACE2, D), Mas-related G protein–coupled receptor (Mas, E), Mas-related G protein-coupled receptor member D (MRGD, F) mRNA gene expressions the in liver of rats fed with high-fat (HF, n=4) or control (CT, n=4) diet for 15 weeks and treated with empty (HP/CD), Ang-(1-7) or A-1317 during the last 7 weeks of diets. Values are expressed as mean ± SEM and analyzed using two-way analysis of variance (ANOVA) followed by Tukey’s post-test. *p<0.05 compared to CT/E group, #p<0.05 compared to HF/E group, &p<0.05 compared to HF/Ang-(1-7) group.](https://www.frontiersin.org/articles/10.3389/fphar.2020.01263/full)
Ang-(1–7) does not change insulin levels and AMPK mRNA gene expression, reduced HOMA-β and QUICKI and increased AKT mRNA gene expression in the liver. This reduction in plasma insulin levels induced by A-1317 treatment may be due to the action of AMPK on direct translocation of glucose transporter type 4 (GLUT-4) to membrane and/or by regulating, positively, insulin receptor substrate 1 (Harrington et al., 2004; Shah et al., 2004) and/or by inhibiting insulin via (mTOR) (Fisher, 2006; Inoki et al., 2012) and therefore improving insulin sensitivity and making glucose levels lower. In fact, in the present study, treatment with A-1317 was more effective in reducing plasma glucose levels compared to treatment with Ang-(1–7). In addition, both insulin and activated AMPK suppress the expression of gluconeogenic enzymes (Lochhead et al., 2000). The molecular mechanisms that lead to the onset of IR are not completely understood. However, it is clear that there is a cross-talk between insulin and Ang II and hormones such as leptin (Coppari and Bjørbaek, 2012), which in the present study was shown by reduction of plasma leptin levels and ATIR hepatic mRNA gene expression induced by both Ang-(1–7) and A-1317 treatments. Additionally, activated AMPK stimulates the catabolic pathways (Hardie et al., 2012), phosphorylates and inhibits acetyl coenzyme A carboxylase and 3-hydroxy 3-methylglutaryl coenzyme A reductase, which are the limiting enzymes of fatty acid and cholesterol biosynthesis, respectively (Lin and Hardie, 2018). Furthermore, AMPK promotes glucose metabolism homeostasis by decreasing free fatty acid concentration and consequently reducing ectopic fat accumulation, preventing hepatic steatosis and the formation of reactive species (Qiu et al.,

**FIGURE 3 |** Evaluation of oxidative stress in the liver. Concentrations of malondialdehyde (MDA, μg/mg of protein) by concentrations of thiobarbituric acid-reactive substances (TBARS) method (A) carbonylated protein (B), endothelial nitric oxide synthase (eNOS) mRNA gene expression (C), inducible nitric oxide synthase (iNOS) mRNA gene expression (D), superoxide dismutase (SOD, E) in the liver of rats fed with high-fat (HF, n=4) or control (CT, n=4) diet for 15 weeks and treated with empty (HP/ICD), Ang-(1-7) or A-1317 during the last 7 weeks of diets. Values are expressed as mean ± SEM and analyzed using two-way analysis of variance (ANOVA) followed by Tukey’s post-test. *p<0.05 compared to CT/E group, †p<0.05 compared to HF/E group, &p<0.05 compared to HF/Ang-(1-7) group.
According to the present study treatment with A-1317, and not treatment with Ang-(1–7), reduced cholesterol plasma levels. Literature data also show that AMPK activity correlates with increased antioxidant enzyme activity (Qiu et al., 2014; Hinchy et al., 2018). Thus, A-1317, and not Ang-(1–7), probably because it acts via AMPK, becomes more efficient in restoring IR, liver damage and improving both glucose and cholesterol metabolism.

Studies show that circulating Ang-(1–7) improves glucose and lipid metabolism by ameliorating insulin pathway and redox process in the liver and gastrocnemius muscle in rats fed with diet H (Oliveira Andrade et al., 2014; Williams et al., 2016; Figueiredo et al., 2019) and fed with fructose diet (Giani et al., 2009; Muñoz et al., 2012; Marcus et al., 2013). In the present study, oral treatment with both Ang-(1–7) and A-1317 improved the redox process in the liver by increasing eNOS mRNA gene expression and SOD activity and reducing MDA, carbonylated protein and iNOS mRNA gene expression compared to HF/E rats. However, oral treatment with A-1317 increased eNOS mRNA gene expression and SOD activity also compared to CT/E rats and thus, the increase in the AMPK mRNA gene expression may have favored the eNOS mRNA gene expression and SOD activity (Garcia-Prieto et al., 2019), which together, may have contributed to the restoration of liver damage observed by normalization of ALT and AST levels that was shown only in the treatment with A-1317.

Although most studies show that Ang-(1–7) acts through AKT-dependent Mas and NO (Sampaio et al., 2007; Muñoz et al., 2012), some studies suggest that Ang-(1–7) may also act through MRGD that shows high Mas homology (Tetzner et al., 2016; Gunarathne et al., 2019). Our data from the present study showed that Ang-(1–7) at MetS does not act through the MRGD but through the Mas, stimulating eNOS activation and probably NO production and reducing protein and lipid oxidation and increasing SOD activity dependent to AKT (Patel et al., 2016). Furthermore, studies suggest that ECA2 mRNA gene expression may be regulated by energy stress and AMPK activation (Patel et al., 2016), besides decreasing the mRNA gene expression of ACE (Kohlstedt et al., 2011; Oliveira Andrade et al., 2014; Liu et al., 2019). In the present study, both oral treatment with Ang-(1–7) and A-1317 increased liver ECA2, Mas and reduced ATIR mRNA gene expression compared with HF/E rats. However, oral treatment with A-1317 also increased angiotensinogen, Mas, MRGD, and AMPK mRNA gene expression in both CT/E and HF/Ang-(1–7) rats and did not increase AKT mRNA gene expression in the liver. These data suggest that although both Ang-(1–7) and A-1317 act on the ECA2/Ang-(1–7)/Mas axis, A-1317 has affinity for both Mas and MRGD, but this new compound, acts preferentially via AMPK, while Ang-(1–7) appears to act primarily on Mas via AKT in MetS rats. Further studies are needed to confirm these findings.

**CONCLUSION**

Our data together show that oral treatment with A-1317 induces similar benefits to treatment with Ang-(1–7) on metabolic disturbances and on blood pressure in rats with MetS. However, oral treatment with A-1317 was more efficient in reducing body mass gain, improving IR, liver damage and β-cell functionality.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

**ETHICS STATEMENT**

The project was approved by the animal ethics committee of the Federal University of Ouro Preto protocol 2016/51.

**AUTHOR CONTRIBUTIONS**

ACA and RASS conceived and designed the experiment, analyzed the data, and wrote the manuscript. CMB, TCL, MAB, and ACA performed the experiments, analyzed the data, and wrote the manuscript. All authors contributed to the article and approved the submitted version.
ACKNOWLEDGMENTS

The authors are grateful for support from the Center of Animal Science (CCA/UFOP), Laboratory of Biochemistry and Molecular Biology and Laboratory of Experimental Physiology and of Laboratory Immunopathology. This study was supported by the Universidade Federal de Ouro Preto (UFOP), Pró-Reitoria de Pós-Graduação (PROPP-UFOP), FAPEMIG (Fundação de Amparo à Pesquisa do Estado de Minas Gerais), CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) and CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior).

REFERENCES

Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., et al. (2009). Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International. Circulation 120 (16), 1640–1645. doi: 10.1161/CIRCULATIONAHA.109.192664

Barbosa, M. A., Guerra-Sá, R., De Castro, U. G. M., de Lima, W. G., dos Santos, R. A. S., Campagnole-Santos, M. J., et al. (2018). Physical training improves the efficiency and insulin pathway, and induces remodeling in white and brown adipose tissues. J. Physiol. Biochem. 74 (3), 441–454. doi: 10.1007/s13103-018-0637-x

Barbosa, M. A., de Sousa, G. G., de Castro, U. G. M., Carneiro, C. M., Figueiredo, V. P., de Sá, R. G., et al. (2019). Oral Ang-(1-7) treatment improves white adipose tissue remodeling and hypertension in rats with metabolic syndrome. Nutr.: X 1, 100004. doi: 10.1016/j.nutx.2019.100004

Coppari, R., and Björnback, C. (2012). The Potential of Leptin for Treating Diabetes and Its Mechanism of Action. Nat. Rev. Drug Discovery 11 (9), 692–708. doi: 10.1038/nrd3757

Dias-Peixoto, M. F., Santos, R. A. S., Gomes, E. R. M., Alves, M. N. M., Almeida, P. W. M., Greco, L., et al. (2008). Molecular mechanisms involved in the angiotensin-(1-7)/mas signaling pathway in cardiomyocytes. Hypertension 52 (3), 542–548. doi: 10.1161/HYPERTENSIONAHA.107.114280

Dieterich, S., Bieylk, U., Beulich, K., Hasenfuss, G., and Prestle, J. (2000). Gene regulation of IRS proteins. J. Cell Biol. 151, 313–318. doi: 10.1083/jcb.151.2.313

Díaz-Pérez, M. F., Santos, R. A. S., Gomes, E. R. M., Alves, M. N. M., Almeida, P. W. M., Greco, L., et al. (2008). Molecular mechanisms involved in the angiotensin-(1-7)/mas signaling pathway in cardiomyocytes. Hypertension 52 (3), 542–548. doi: 10.1161/HYPERTENSIONAHA.107.114280

Fischer, J. S. (2006). Potential Role of the AMP-activated Protein Kinase in Regulation of Insulin Action. Cellsciences 2 (3), 68–81. doi: 10.2337/ diabetes.53.8.1953

Fu, A., Eberhard, C. E., and Screaton, R. A. (2013). Role of AMPK in pancreatic beta cell function. Mol. Cell. Endocrinol. 366 (2), 127–134. doi: 10.1016/j.mce.2012.06.020

Garcia-Prieto, C. F., Gil-Ortega, M., Plaza, A., Javier Manzano-Lista, F., Gonzalez-Blazquez, R., Alcalá, M., et al. (2019). Caloric restriction induces H2O2 formation as a trigger of AMPK-eNOS-NO pathway in obese rats: Role for catalase in the end-stage failing heart. Circulation 110 (1), 33–39. doi: 10.1161/CIRC.110.131113

Hardie, D. G., Ross, F. A., and Hawley, S. A. (2012). AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13 (4), 251–262. doi: 10.1038/nrm3311

Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., et al. (2004). The TSC1-2 tumor suppressor controls insulin-P13K signaling via regulation of IRS proteins. J. Cell Biol. 166 (2), 213–223. doi: 10.1083/jcb.200403069

Hinchy, E. C., Gruszczcyk, A. V., Willows, R., Navaratnam, N., Hall, A. R., Bates, G., et al. (2018). Mitochondria-derived ROS activate AMP-activated protein kinase (AMPK) indirectly. J. Biol. Chem. 293 (44), 17208–17217. doi: 10.1074/jbc.RA118.025279

Iwaki, K., Kim, J., and Guan, K.-L. (2012). AMPK and mTOR in Cellular Energy Homeostasis and Drug Targets. Annu. Rev. Pharmacol. Toxicol. 52 (1), 381–400. doi: 10.1146/annurev-pharmtox-010611-134537

Keneko, Y. K., and Ishikawa, T. (2013). Dual role of nitric oxide in pancreatic β-cells. J. Pharmacol. Sci. 123 (4), 295–300. doi: 10.1254/jfps.13010CP

Kohlstedt, K., Trouvain, C., Namgaladze, D., and Fleming, I. (2011). Adipocyte-derived lipids increase angiotensin-converting enzyme (ACE) expression and modulate macrophage phenotype. Basic Res. Cardiol. 106 (2), 205–215. doi: 10.1007/s00395-010-0137-9

Levine, R. L., Garland, D., Oliver, C. N., Amici, A., Climent, L., Lenz, A. G., et al. (1990). Determination of Carbonyl Content in Oxidatively Modified Proteins. Methods Enzymol. 186 (C), 464–478. doi: 10.1016/S0076-6879(90)63411-H

Lin, S. C., and Hardie, D. G. (2018). AMPK: Sensing Glucose as well as Cellular Energy Status. Cell Metab. 27 (2), 299–313. doi: 10.1016/j.cmet.2017.10.009

Liu, J., Li, X., Lu, Q., Ren, D., Sun, X., Rousselle, T., et al. (2019). AMPK: A balance of the renin–angiotensin system. Biosci. Rep. 39 (9), 1–18. doi: 10.1042/BSR20181994

Llochhead, P. A., Salt, I. P., Walker, K. S., Hardie, D. G., and Sutherland, C. (2000). 5-Aminooimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key glucosegenic genes PEPCK and glucose-6-phosphatase. Diabetes 49 (6), 896–903. doi: 10.2337/diabetes.49.6.896

Marcus, Y., Shefer, G., Sasson, K., Cohen, F., Limor, R., Pappo, O., et al. (2013). Angiotensin 1-7 as means to prevent the metabolic syndrome lessons from the fructose-fed rat model. Diabetes 62 (4), 1121–1130. doi: 10.2337/db12-0792

Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., and Turner, R. C. (1985). Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (7), 412–419. doi: 10.1007/BF00280883

Mears, G. P., Hughes, K. J., Naatiz, A., Papa, F. R., Urano, F., Hansen, P. A., et al. (2011). IRE1-Dependent Activation of AMPK in Response to Nitric Oxide. Mol. Cell. Biol. 31 (21), 4286–4297. doi: 10.1128/mcb.05668-11

Muñoz, M. C., Giani, J. F., Burghi, V., Mayer, A. M., Carranza, A., Taira, C. A., et al. (2012). The Mas receptor mediates modulation of insulin signaling by angiotensin-(1-7). Regul. Peptides 177 (1–3), 1–11. doi: 10.1016/j.regpep.2012.04.001

Oliveira, A. F., Garcia, Z. M., Ferreira, A. V. M., Sinisterra, R. D. M., Sousa, F. B., et al. (2014). Cross talk between angiotensin-(1-7)/Mas axis and sirtuins in adipose tissue and metabolism of high-fat feed mice. Peptides. 55, 158–165. doi: 10.1016/j.peptides.2014.03.006

Oliveira, M. F. (2019). Avaliação farmacocinética e farmacodinâmica do análogo da angiotensina-(1-7), o A-1317 [manuscrito] (Orientador: Robson Augusto dos Santos, Tese (Doutorado) Fisiologia e Biofísica - Universidade Federal de Minas Gerais).

Peluso, I., Palmeny, M., and Drummen, G. (2017). Biomarkers of Oxidative Stress in Experimental Models and Human Studies with Nutraceuticals:
Shah, O. J., Wang, Z., and Hunter, T. (2004). Inappropriate activation of the TSC/Rheb/ Song, A. W., Emberger, K., Michelich, C. R., and McCarthy, G. (2004). FMRI Sampaio, W. O., Dos Santos, R. A. S., Faria-Silva, R., Da Mata Machado, L. T., Schiffin, E. I., and Touyz, R. M. (2007). Angiotensin-(1–7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49 (1), 185–192. doi: 10.1161/01.HYP.0000251865.35728.2f Santos, R. A. S., Haibara, A. S., Campagnole-Santos, M. J., Simões e Silva, A. C., Paula, R. D., Pinheiro, S. V. B., et al. (2003). Characterization of a new selective antagonist for angiotensin-(1–7): D-Pro7-angiotensin-(1–7). Hypertension 41, 737–743. doi: 10.1161/01.HYP.0000052947.60362.24 Santos, S. H. S., Giani, J. F., Burghi, V., Miquet, J. G., Qadri, F., Braga, J. F., et al. (2014). Oral administration of angiotensin-(1–7) ameliorates type 2 diabetes in rats. J. Mol. Med. 92 (3), 255–265. doi: 10.1007/s00109-013-1087-0 Santos, R. A. S., Sampiao, W. O., Alzamora, A. C., Motta-Santos, D., Alenina, N., Bader, M., et al. (2018). The ACE2/ Angiotensin-(1–7)/ Mas axis of the renin-angiotensin system: Focus on angiotensin-(1–7). Physiol. Rev. 98, 505–553. doi: 10.1152/physrev.00023.2016 Sarafidis, P. A., Lasaridis, A. N., Nilsson, P. M., Pikidiou, M.II, Stafilas, P. C., Kanaki, A., et al. (2007). Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. J. Hum. Hypertension 21 (9), 709–716. doi: 10.1038/sj.jhh.1002201 Shah, O. J., Wang, Z., and Hunter, T. (2004). Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14 (18), 1650–1656. doi: 10.1016/j.cub.2004.08.026 Song, A. W., Emberger, K., Michelich, C. R., and McCarthy, G. (2004). FMRI signal source analysis using diffusion-weighted spiral-in acquisition. Annu. Int. Conf. IEEE Eng. Med. Biol. - Proc. 26 VI, 4417–4420. doi: 10.1109/iembs.2004.1404228 Tetzner, A., Gebolys, K., Meinert, C., Klein, S., Uhlich, A., Trebicka, J., et al. (2016). G-Protein-Coupled Receptor MrgD Is a Receptor for Angiotensin-(1–7) Involving Adenylyl Cyclose, cAMP, and Phosphokinase A. Hypertension 68 (1), 185–194. doi: 10.1161/HYPERTENSIONAHA.116.07572 Vona, R., Gambardella, L., Cittadini, C., Straface, E., and Pietraforta, D. (2019). Biomarkers of oxidative stress in metabolic syndrome and associated diseases. Oxid. Med. Cell. Longevity 8267234, 19. doi: 10.1155/2019/8267234 Whitaker, A. M., and Molina, P. E. (2014). Angiotensin (1–7) contributes to nitric oxide tonic inhibition of vasopressin release during hemorrhagic shock in acute ethanol intoxicated rodents. Intoxicated Rodents 93 (17), 623–629. doi: 10.11016/j.jlbs.2013.08.020.Angiotensin Williams, I. M., Otero, Y. F., Bracy, D. P., Wasserman, D. H., Biaggioni, I., and Arnold, A. C. (2016). Chronic angiotensin-(1–7) improves insulin sensitivity in high-fat fed mice independent of blood pressure. Hypertension 67 (5), 983–991. doi: 10.1161/HYPERTENSIONAHA.115.06935 Zacarias, A. C., Barbosa, M. A., Guerra-Sá, R., De Castro, U. G. M., Bezerra, F. S., de Lima, W. G., et al. (2017). Swimming training induces liver adaptations to oxidative stress and insulin sensitivity in rats submitted to high-fat diet. Redox Rep. 22 (6), 515–523. doi: 10.1080/13510002.2017.1315513 Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Copyright © 2020 Barbosa, Barbosa, Lima, Santos and Alzamora. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.